Research Paper

Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens

Lei Zhao, Jing Yu, Jing Wang, Huihui Li, Juanjuan Che, Bangwei Cao

Cancer center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Corresponding author: Dr. Bangwei Cao, Cancer center, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xicheng District, Beijing 100050, China. TEL: +86-010-63139321, Fax: +86-010-63139321, E-mail address: oncology@ccmu.edu.cn.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Abstract

Objective: To compare the incidence and severity of diarrhea among different tumor types and treatment regimens, and also compared with CTLA-4 inhibitors in randomized controlled trials.

Methods: MEDLINE, PMC database and EMBASE were retrieved until December 2018. Studies were eligible if they were randomized controlled trials and included participants undergoing PD-1/PD-L1 inhibitors for cancer, measured a treatment side effect of diarrhea, and reported quantitative data. The risks of diarrhea in PD-1/PD-L1 inhibitors were compared among different treatment regimens.

Results: Totally 21 studies involving 11,554 patients were included for meta-analysis. For all-grade diarrhea, the risk after the PD-1/PD-L1 inhibitors plus CTLA-4 inhibitor combination was 1.90 times significantly higher than that of monotherapy, and the risk was 0.69 and 0.60 times significantly lower than that of monotherapy compared with chemotherapy and ipilimumab. The incidence of diarrhea was not significantly different between PD-1/PD-L1 inhibitor monotherapy versus placebo or between low-doses versus high-doses. For high-grade (grade ≥ 3) diarrhea, the risk after the PD-1/PD-L1 inhibitors plus CTLA-4 inhibitor combination was 3.29 times significantly higher than that of monotherapy, the risk in PD-1/PD-L1 inhibitors monotherapy was 0.50 and 0.38 times significantly lower than chemotherapy and ipilimumab respectively. No significant difference was found in the incidence of diarrhea between PD-1/PD-L1 inhibitor monotherapy versus placebo or between low-doses versus high-doses whether in all-grade or high-grade group.

Conclusions: PD-1/PD-L1 inhibitors have a lower risk of developing diarrhea than chemotherapy and CTLA-4 inhibitor. There is no direct relationship between the dose of PD-1/PD-L1 inhibitors and the risk of developing diarrhea.

Key words: Cancer; Diarrhea; Randomized controlled trials; PD-1/PD-L1 inhibitors; CTLA-4 inhibitor; Chemotherapy

Introduction

Increasing evidence proves the significant efficacy of immune checkpoint inhibitors (ICIs) in treatment of advanced cancers [1-4]. ICIs targeting the programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) pathway significantly improve the progression-free survival and overall survival compared with standard chemotherapy, so PD-1/PDL1 antibodies are currently approved for treatment of various malignancies [5-11]. Since the anti-PD-1 antibody pembrolizumab was approved in September 2014 for treatment of advanced melanoma, the clinical development of PD-1/PD-L1 inhibitors as anticancer drugs has been widely expanded. Currently, the Food and Drug Administration has
approved PD-1/PD-L1 inhibitors for treatment of 9 types of cancers. For instance, pembrolizumab can be used to treat melanoma [2, 12-14], non-small cell lung cancer (NSCLC) [7, 15-19], head and neck squamous cell carcinoma (HNSCC) [20], Hodgkin's lymphoma [21], urothelial cancer [22, 23] and gastric cancer [24]. Anti-PD-1 antibody nivolumab is recommended for treating melanoma [11, 25], renal cell carcinoma (RCC)[26], Hodgkin's lymphoma [27, 28], urine epidermal cancer [29], MSI-H colon cancer [30] and hepatocellular carcinoma [31]. Anti-PD-L1 antibody atezolizumab is suggested for treatment of urothelial cancer [22, 32] and NSCLC [6, 33], and anti-PD-L1 antibodies avelumab and durvalumab can be used to treat urothelial cancer[34, 35]. Compared with cytotoxic chemotherapy, ICIs have unique toxicity based on their action mechanism, which is considered to be immune-related adverse event (IRAE) [36-39]. Inhibiting the PD-1/PD-L1 pathway may lead to autoimmune toxicity, some of which may be severe or even life-threatening [36, 40].

Diarrhea is a common side effect of cancer treatment that, in severe cases, can lead to death or to patients having to stop lifesaving treatment because often there are no effective therapies to control the diarrhea. Diarrhea in cancer patients can quickly lead to life-threatening consequences such as dehydration, electrolyte imbalance, shock, etc. Compared to chemotherapy-related diarrhea the immunological preparation of PD-1/PD-L1 is prone to cause autoimmune digestive diseases such as ulcerative colitis, and may also cause side effects of diarrhea.

Given the clinical efficacy evidence for a wide spectrum of tumor types, the PD-1 ICI therapy is expected to be increasingly used by oncologists as a monotherapy or in combination with other drugs. Therefore, physicians in cancer immunotherapy must be familiar with the pathogenesis of diarrhea in different tumors and different treatment regimens, and provide useful information to optimize the management of this toxicity. At present, there is no complete description about the clinical experience of anti-PD-1/PD-L1-associated diarrhea patients, or about the management and outcome of this toxicity. Therefore, we conducted a meta-analysis of PD-1 inhibitors in cancer patients and compared the incidence and severity of diarrhea among different tumor types, different treatment regimens.

1. Methods

1.1. Literature selection and data extraction

Two researchers (Lei Zhao and Huihui Li) independently reviewed the databases Medline, PMC database and EMBASE to select potential relevant articles. Any discrepancy between them was resolved by consensus. The following medical subject heading terms were used: PD-1, PD-L1, CD274, programmed death receptor 1, programmed death receptor ligand, immune checkpoint inhibitor, nivolumab, BMS936558, pembrolizumab, MK-3475, MPDL3280A, atezolizumab, avelumab, MSB0010718C, durvalumab, and diarrhea. The databases were searched from the inception until December, 2018.

The inclusion criteria were: (a) phase I, II and III trials in cancer patients; (b) random assignment of participants to single PD-1/PD-L1 inhibitor treatment or other control therapy (e.g. ipilimumab, placebo); (c) reporting diarrhea events or event rate and sample size for any all-grade or high-grade (≥3) adverse events;(d) random controlled trial.

The following information was extracted by two independent reviewers (Lei Zhao and Huihui Li) from the included studies: first author, publication year, study name, clinical trial registration number, total number of patients, mean age, trial phase, treatment plan, tumor type, primary inclusion criteria, and numbers of patients with all grades and high-grade treatment-related diarrhea. The treatment regimens were classified as PD-1/PD-L1 inhibitor monotherapy, PD-1/PD-L1 inhibitor plus CTLA-4 inhibitor ipilimumab, chemotherapy, placebo, and ipilimumab. According to the different doses, monotherapy was divided into low-dose group and high-dose group.

1.2. Quality assessment

The two reviewers (Lei Zhao, Huihui Li) used the Jadad scoring method[41] to evaluate the quality of each included study from randomized (0 or 1), double-blind (0, 1 or 2), recorded loss of follow-up and/or exit (0 or 1) and assign hidden (0 or 1). A score ≥ 3 indicates high quality.

1.3. Statistical analysis

Meta-analysis for statistical analysis was performed using Stata12.1 (Stata Corp, College Station, TX, USA). Heterogeneity was analyzed by Q test, and I²<25%, 25%-75%, and >75% indicate mild, moderate and significant heterogeneity, respectively. In case of insignificant heterogeneity between studies indicated as P>0.05, a fixed effect model was used; otherwise a random effect model was used. The incidence of diarrhea was evaluated by relative risk (RR) and 95% confidence interval (CI), and the analysis results were represented by forest maps. Two-tailed p < 0.05 was considered significant. This meta-analysis has been registered on the PROSPERO website (Registration Number: CRD42018111834).
2. Results

The database search initially returned 4021 studies. After screening and eligibility assessment, a total of 21 randomized controlled trials (RCTs, n=11554 patients) were identified for meta-analysis. ICIs tested in these studies included nivolumab (n=13 studies), pembrolizumab (n=6), avelumab (n=1) and durvalumab (n=1). Tumor types tested included NSCLC (n=7 studies), melanoma (n=10), HNSCC (n=1), Renal Cell Carcinoma (RCC) (n=1), gastric cancer (n=1) and small cell lung cancer (SCLC) (n=1). According to the clinical staging, 15, 5 and 1 of the 21 RCTs were at phase 3, 2 and 1, respectively (Table 1, Figure 1).

2.1. Risks of diarrhea among different treatment regimens

All-grade diarrhea

The risks of all-grade diarrhea in PD-1/PD-L1 inhibitors were compared among different treatment regimens: PD-1/PD-L1 inhibitor monotherapy versus PD-1/PD-L1 inhibitor plus ipilimumab, versus chemotherapy, versus placebo, versus ipilimumab, and high-dose versus low-dose in the 20 studies (Figure 2).

PD-1/PD-L1 inhibitor monotherapy versus placebo

Two RCTs [42, 43] compared PD-1/PD-L1 inhibitor monotherapy and placebo (n=1,720 patients). Classification based on tumor type included melanoma (n = 1 study) and NSCLC (n = 1). Classification according to the use of ICIs included pembrolizumab (n = 1) and durvalumab (n = 1). The pooled RR of all-grade diarrhea incidence was not significant after PD-1/PD-L1 inhibitor monotherapy (RR 1.07, 95%CI: 0.87-1.32, P=0.516) (Figure 2A).

PD-1/PD-L1 inhibitor monotherapy versus chemotherapy

Eleven RCTs [5, 7, 11, 12, 18, 44-49] compared PD-1/PD-L1 inhibitor monotherapy and conventional chemotherapy (n=5,915 patients). Classification according to tumor type included melanoma (n = 3 study), HNSCC (n=1), Gastric cancer (n=1) and NSCLC (n = 6). Classification according to the use of ICIs included nivolumab (n = 7 study), pembrolizumab (n = 3) and Avelumab (n=1). The risk of all-grade diarrhea after PD-1/PD-L1 inhibitor monotherapy was significantly decreased (RR 0.69, 95%CI: 0.49-0.98, P=0.037; Figure 2B). The risk of all-grade diarrhea after PD-1/PD-L1 inhibitor monotherapy in Carcinoma of the Head and Neck and Gastric cancer patients were significantly decreased (RR 0.50, 95%CI: 0.26-0.98, P=0.043; RR 0.23, 95%CI: 0.12-0.42, P=0.000 Figure 2B).

PD-1/PD-L1 inhibitor monotherapy versus ipilimumab

Three RCTs [13, 50, 51] compared PD-1/PD-L1 inhibitor monotherapy and ipilimumab (n=2,596 patients). The tumor type was malignant melanoma. Classification according to the use of ICIs was nivolumab (n=2) and pembrolizumab (n=1). The study group of Caroline Robert 2015[13] was divided into two subgroups according to drug intervals and thus can be analyzed as two studies. The pooled RR of all-grade diarrhea incidence after the PD-1/PD-L1 inhibitor monotherapy (nivolumab or pembrolizumab) was significantly decreased (RR 0.60, 95%CI: 0.53-0.68, P=0.000; Figure 2C).

Nivolumab plus ipilimumab compared to nivolumab monotherapy

Four RCTs [42, 48, 50, 52] compared nivolumab plus ipilimumab and nivolumab monotherapy (n= 1,805 patients). Classification of tumor type was SCLC (n=1 study), NSCLC (n=1) and melanoma (n=2). Our meta-analysis reveals that nivolumab plus ipilimumab significantly increased the risk of all-grade diarrhea compared to nivolumab monotherapy (RR 1.90, 95%CI: 1.58-2.30, P=0.000; Figure 2D).
Figure 2. The risks of all-grade diarrhea in PD-1/PD-L1 inhibitors were compared among different treatment regimens.
### Table 1. Characteristics of Relevant Studies

| Analysis Method | Source | Format | Data Set | Tumor Type | Main Inclusion Criterion | Treatment | Sample Size | Age, Median(range), Jadad score |
|-----------------|--------|--------|----------|------------|---------------------------|-----------|-------------|--------------------------------|
| Meta-analysis   | R.L. Ferris 2016 CheckMate 141 NCT02109366 | Full text | Randomized, open-label, phase 3 trial | Head and neck | Recurrent squamous-cell carcinoma of the head and neck | 1. Nivolumab 3 mg/kg Q2W<br>2. Standard therapy | 240<br>121 | 59(29–83)<br>61(28–78) | 3 |
|                 | Julie Brahmer 2015 CheckMate 017 NCT01642004 | Full text | Randomized, open-label, international, phase 3 study | NSCLC | Stage IIIb or IV squamous-cell NSCLC | 1. Nivolumab 3 mg/kg Q2W<br>2. Docetaxel 75 mg/m2 Q3W | 135<br>137 | 62 (39–85)<br>64 (42–84) | 3 |
|                 | Caroline Robert 2015 KEYNOTE-006 NCT01866319 | Full text | Randomized, controlled, phase 3 study | Melanoma | Unresectable stage III or IV melanoma | 1. Pembrolizumab 10 mg/kg Q2W<br>2. Pembrolizumab 10 mg/kg Q3W | 279<br>278 | 61 (18–89)<br>62 (18–88) | 3 |
|                 | Omid Hamid 2017 KEYNOTE-002 NCT01704287 | Full text | Randomised, open-label, phase 2 study | Melanoma | Unresectable stage III or IV melanoma not amenable to local therapy | 1. Pembrolizumab 2 mg/kg Q3W<br>2. Pembrolizumab 10 mg/kg Q3W | 180<br>179 | 62 (15–87)<br>63 (27–87) | 3 |
|                 | J.D. Wolchok 2017 CheckMate 067 NCT01844835 | Full text | Double-blind, Randomised, phase 3 trial | Melanoma | Stage III (unresectable) or stage IV melanoma | 1. Nivolumab 1 mg/kg Q3W plus ipilimumab 3 mg/kg Q3W for four doses followed by nivolumab 3 mg/kg Q2W<br>2. Nivolumab 3 mg/kg Q2W<br>3. Ipilimumab 3 mg/kg Q2W for four doses | 314<br>315 | 61 (18–88)<br>62 (18–89) | 4 |
|                 | Michael A. Postow 2015 NCT01927419 | Full text | Randomised, 2:1 in a double-blind phase 2 trial | Melanoma | Unresectable, previously-untreated, stage III or IV melanoma with measurable disease | 1. Nivolumab 1 mg/kg Q3W plus ipilimumab 3 mg/kg first 4 doses, then nivolumab 3 mg/kg Q2W<br>2. Ipilimumab 3 mg/kg first 4 doses | 95<br>47 | 64 (27–87)<br>67 (31–80) | 4 |
|                 | Georgina V Long 2018 NCT02037424 | Full text | Multicentre, open-label randomised, phase 2 trial | Melanoma brain metastases | | 1. Nivolumab 1 mg/kg + ipilimumab 3 mg/kg Q3W for four doses; then nivolumab 3 mg/kg Q2W<br>2. Nivolumab 3 mg/kg Q2W<br>3. Nivolumab 3 mg/kg Q2W (brain metastases) | 35<br>25<br>16 | 59 (53–68)<br>63 (52–74)<br>51 (46–56) | 3 |
|                 | Caroline Robert 2014 KEYNOTE-001 NCT01395827 | Full text | Open-label, international, multicentre, phase 3 trial | Melanoma | Progressive, measurable, unresectable melanoma | 1. Pembrolizumab 2 mg/kg Q3W<br>2. Pembrolizumab 10 mg/kg Q3W | 89<br>84 | 57 (18–88)<br>60 (27–86) | 3 |
|                 | Alexander M.M. Eggermont 2018 NCT02362994 | Full text | Randomized, double-blind phase 3 trial | Melanoma | Resected stage III melanoma | 1. Pembrolizumab 200 mg Q3W for 18 doses<br>2. Placebo | 514<br>505 | 54 (19–88)<br>54 (19–83) | 4 |
|                 | S.J. Antonia 2017 PACIFIC NCT02125461 | Full text | Global, randomized, phase 3 trial | NSCLC | Stage III, locally advanced, unresectable NSCLC | 1. Durvalumab/10 mg/kg Q2W for up to 12 months<br>2. Placebo | 476<br>237 | 64(31–84)<br>64(23–90) | 3 |
|                 | Martin Reck 2016 KEYNOTE-024 NCT02142734 | Full text | Open-label, randomised, phase 3 trial | NSCLC | Untreated advanced NSCLC with PD-L1 expression on at least 50% of tumour cells kinase gene | 1. Pembrolizumab 200 mg Q3W for 35 cycles<br>2. Investigator’s choice of platinum based chemotherapy for 4 to 6 cycles | 154<br>151 | 64.5(33–90)<br>66(38–85) | 3 |
|                 | D.P. Carbone 2017 CheckMate 026 NCT02041533 | Full text | Open-label randomized phase 3 trial | NSCLC | Untreated stage IV or recurrent NSCLC and a PD-L1 tumour-expression level of 1% or more | 1. Pembrolizumab 2 mg/kg Q3W<br>2. Platinum-based chemotherapy Q3W for up to six cycles | 271<br>270 | 63(32–89)<br>65(29–87) | 3 |
|                 | Roy S Herbst 2016 KEYNOTE-010 NCT01905657 | Full text | Randomised, open-label, phase 2/3 study | NSCLC | Previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells | 1. Pembrolizumab 2 mg/kg Q3W<br>2. Pembrolizumab 10 mg/kg Q3W<br>3. Docetaxel 75 mg/m2 Q3W | 344<br>346<br>343 | 63 (56–69)<br>63 (56–69)<br>62 (56–69) | 3 |
| Meta-analysis   | Scott J Antonia 2016 CheckMate 022 NCT01928394 | Full text | Randomised,Co hort of this phase 1/2 multicentre, multi-arm, open-label trial | Recurrent small-cell lung cancer | Limited-stage or extensive-stage SCLC, and had disease progression after at least one previous platinum-containing regimen | 3. Docetaxel 75 mg/m2 Q3W<br>1. Nivolumab 3 mg/kg Q2W<br>2. Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg Q3W for four cycles, nivolumab3 mg/kg Q2W<br>3. Nivolumab 3 mg/kg plus ipilimumab 3 mg/kg Q2W for four cycles, nivolumab3 mg/kg Q2W<br>4. Nivolumab 3 mg/kg Q2W | 98<br>61<br>54 | 63 (57–68)<br>66 (58–71)<br>61 (56–65) | 3 |
|                 | M.D. Hellmann 2018 CheckMate 227 NCT02477826 | Full text | Randomised, open-label phase 3 trial | stage IV or recurrent NSCLC | stage IV or recurrent NSCLC that was not previously treated with chemotherapy | 1. Nivolumab 3 mg/kg Q2W plus Ipilimumab 1 mg/kg Q2W<br>2. Nivolumab 240 mg Q2W | 576<br>391<br>570 | -<br>3 | 3 |

http://www.jcancer.org
High-dose group versus low-dose group

Three RCTs [7, 26, 47] compared the low-dose and high-dose PD-1/PD-L1 inhibitor monotherapy (n= 1039 patients). Pembrolizumab 2 mg/kg is defined as low dose; 10 mg/kg is high-dose. Nivolumab ≤2 mg/kg is defined as low dose, 10 mg/kg is high-dose. Classification according to tumor type was melanoma (n = 1 study), RCC (n = 1) and NSCLC (n = 1). Results showed no significant risk in the high-dose group (RR 1.15, 95%CI: 0.80-1.67, P=0.446; Figure 2E).

High-grade diarrhea

Figure 3 showed the risk of high-grade (≥ 3) diarrhea according to different treatment regimens: PD-1/PD-L1 inhibitor monotherapy versus PD-1/PD-L1 inhibitor plus ipilimumab, versus chemotherapy, versus placebo, versus ipilimumab, and low-dose versus high-dose.

PD-1/PD-L1 inhibitor monotherapy versus placebo

Inclusion of the study and number of patient’s high-grade diarrhea were consistent with previous all-grade diarrhea. Results showed a significant decreased in the risk of high-grade diarrhea after monotherapy (RR 0.50, 95%CI: 0.26-0.95, P = 0.035; Figure 3B). Of the 7 RCTs on non-small cell lung cancer, 5 were treated with nivolumab and 2 with pembrolizumab. The use of nivolumab or pembrolizumab seems to reduce the risk of diarrhea compared to chemotherapy, but the results are not significant (RR 0.58, 95%CI: 0.25-1.31, P = 0.190; RR 0.61, 95%CI: 0.03-13.01, P = 0.754, respectively).

PD-1/PD-L1 inhibitor monotherapy versus ipilimumab

Inclusion of the study and number of patients of high-grade diarrhea were consistent with previous all-grade diarrhea. Results showed a significant decrease in the risk of high-grade diarrhea after monotherapy (RR 0.50, 95%CI: 0.26-0.95, P = 0.035; Figure 3B). Of the 7 RCTs on non-small cell lung cancer, 5 were treated with nivolumab and 2 with pembrolizumab. The use of nivolumab or pembrolizumab seems to reduce the risk of diarrhea compared to chemotherapy, but the results are not significant (RR 0.58, 95%CI: 0.25-1.31, P = 0.190; RR 0.61, 95%CI: 0.03-13.01, P = 0.754, respectively).

PD-1/PD-L1 inhibitor monotherapy versus chemotherapy

Inclusion of the study and number of patients of high-grade diarrhea were consistent with previous all-grade diarrhea. Results showed a significant decrease in the risk of high-grade diarrhea after monotherapy (RR 0.50, 95%CI: 0.26-0.95, P = 0.035; Figure 3B). Of the 7 RCTs on non-small cell lung cancer, 5 were treated with nivolumab and 2 with pembrolizumab. The use of nivolumab or pembrolizumab seems to reduce the risk of diarrhea compared to chemotherapy, but the results are not significant (RR 0.58, 95%CI: 0.25-1.31, P = 0.190; RR 0.61, 95%CI: 0.03-13.01, P = 0.754, respectively).

PD-1/PD-L1 inhibitor monotherapy versus placebo

Inclusion of the study and number of patient’s high-grade diarrhea were consistent with previous all-grade diarrhea. As shown in Figure 3A, when compared with placebo, there was not a significant increase in the risk of high-grade diarrhea incidence for PD-1/PD-L1 inhibitor monotherapy (RR 0.85, 95%CI: 0.29-2.44, P=0.756).

PD-1/PD-L1 inhibitor monotherapy versus chemotherapy

Inclusion of the study and number of patient’s high-grade diarrhea were consistent with previous all-grade diarrhea. Results showed a significant decrease in the risk of high-grade diarrhea after monotherapy (RR 0.50, 95%CI: 0.26-0.95, P = 0.035; Figure 3B). Of the 7 RCTs on non-small cell lung cancer, 5 were treated with nivolumab and 2 with pembrolizumab. The use of nivolumab or pembrolizumab seems to reduce the risk of diarrhea compared to chemotherapy, but the results are not significant (RR 0.58, 95%CI: 0.25-1.31, P = 0.190; RR 0.61, 95%CI: 0.03-13.01, P = 0.754, respectively).
Figure 3. The risk of high-grade (≥ 3) diarrhea according to different treatment regimens.

High-dose group versus low-dose group

Three RCTs [7, 12, 47] compared the High-dose and Low-dose treatments (n=1,212 patients). Classification of tumor type was melanoma (n=2 studies) and NSCLC (n=1). Results showed no significant increase in the risk of high-grade diarrhea after high-dose treatment (RR 1.86, 95%CI: 0.51-6.79, P=0.345; Figure 3F).

Study quality and publication bias

Fifteen trials were open label, whereas five trials were double blind controlled. The Jadad score ranged from 3 to 4. For RR of all-grade between PD-1/PD-L1 inhibitor monotherapy and chemotherapy or high-grade diarrhea between the monotherapy and ipilimumab, the Egger test suggested some evidence of publication bias. No evidence of bias was found in other comparisons of Egger tests (all P >0.05), or in all Begg tests (all P>0.05).

3. Discussion

Although an increasing number of clinical studies have confirmed the overall survival benefit of PD-1/PD-L1 inhibitors treatment, PD-1/PD-L1 inhibitors therapy increases the toxicity of the drug remains controversial, especially diarrhea. Our meta-analysis is the first large-scale analysis of different immunologic treatment regimens compared with chemotherapy or ipilimumab for the toxic side effects of diarrhea. In our research, the risk of all-grade diarrhea after the PD-1/PD-L1 inhibitors plus CTLA-4 inhibitor combination was 1.90 times higher than that of PD-1/PD-L1 inhibitors monotherapy (P<0.05), and the risk was 0.72 and 0.60 times higher than that of chemotherapy and ipilimumab compared with monotherapy (P<0.05). Chemotherapy is the most prone to diarrhea, followed by PD-1/PD-L1 inhibitors plus CTLA-4 inhibitor combination, and finally PD-1/PD-L1 inhibitors monotherapy. When compared with placebo, we did not observe a significant increase in the risk of all-grade or severe diarrhea incidence, and our meta-analysis also reveals that high-dose PD-1/PD-L1 inhibitor monotherapy did not increase the risk of all-grade or severe diarrhea when compared with low-dose(all P>0.05), which suggested that PD-1/PD-L1 inhibitor monotherapy is relatively safe. The risk of grade ≥ 3 diarrheas for PD-1/PD-L1 inhibitors alone significantly decreased than chemotherapy or ipilimumab, while
the PD-1/PD-L1 inhibitors plus CTLA-4 inhibitor combination significantly increase than monotherapy.

The basic principle of binding PD-1 / PD-L1 inhibitors and CTLA-4 inhibitors is that they have different mechanisms of action. Anti-CTLA-4 mainly acts on the lymph node area, restores the induction and proliferation of activated T cells, and resists PD-1 acts mainly on the periphery of the tumor site, preventing the tumor-infiltrating tumor-infiltrating PD-L1-expressing tumor and plasma-like dendritic cells from neutralizing cytotoxic T cells [53]. Our result found that patients taking CTLA-4 inhibitors ipilimumab had a significantly higher risk of developing diarrhea than those using PD-1 / PD-L1 inhibitors. This is likely to be related to the different mechanisms of action of the two drugs. Although the combination of PD-1/PD-L1 inhibitors plus CTLA-4 inhibitor has achieved good efficacy [25, 50, 52], the corresponding toxic side effects of combination therapy, especially diarrhea, are significantly higher than those of PD-1/PD-L1 inhibitors alone. Combination therapy with both CTLA-4 and PD-1 blockers raised the risk of GI toxicities to about 45% which is much higher than monotherapy [54]. The risk of diarrhea was significantly different compared to the use of PD-1/PD-L1 inhibitors alone and chemotherapy in different tumor types. In patients with NSCLC patients, the risk of diarrhea using PD-1 / PD-L1 inhibitors monotherapy is significantly lower than that of patients receiving chemotherapy. However, this result did not find in melanoma patients. Our results show that patients taking pembrolizumab or nivolumab have a slightly different risk of all-grade diarrhea compared with chemotherapy [11, 12, 47]. Furthermore, our study demonstrates no significant difference in the incidence of diarrhea between low-dose versus high-dose PD-1/PD-L1 inhibitors, which are consistent with another study [12]. This provides reliable evidence for further exploration of adjusting drug doses in future clinical trial design and clinical practice.

As far as we know, this is the systematic review including the largest number of RCTs for analysis of immune-related diarrhea. The present study has some limitations. Firstly, these relevant studies have applied PD-1/PD-L1 inhibitors to different treatment lines, and there may be inconsistencies in the underlying characteristics of the patients. Secondly, since the present study is based on a secondary analysis of the final results of each report, we were unable to obtain patient-level disease characteristics and variables, or to determine the specific risk factors associated with the development of immune-related diarrhea. Thirdly, our results were influenced by the limitations of individual clinical trial design. Some of the clinical trials included in the meta- analysis were open label, which may lead to subjective bias. Finally, clinical RCTs included in the meta-analysis had strict inclusion and exclusion criteria. The patients selected in the study were with good PS, but in clinical practice, a large number of patients suffered impaired organ dysfunction and/or functional status and may have a higher incidence of actual toxicity. In the future, large-sample RCTs are needed to compare the incidence and severity of PD-1/PD-L1 inhibitor associated diarrhea among more tumor types and among more combination regimens.

Overall, PD-1/PD-L1 inhibitors have a lower risk of developing diarrhea than chemotherapy and CTLA-4 inhibitor. There is no direct relationship between the dose of PD-1/PD-L1 inhibitors and the risk of developing diarrhea. This study provides reliable evidence for further exploring the combination of PD-1/PD-L1 inhibitors with other drugs in clinical trial design and clinical practice.

Acknowledgements

Funding & Support

This work was supported by grants from the Beijing Natural Science Foundation (grant number 7184200 to Lei Zhao); Beijing Municipal Administration of Hospitals’ Youth Programme (grant number QML20170102 to Lei Zhao); Beijing Municipal Administration of Hospitals’ Digestive Medical Coordinated Development Center Funding Suppor (grant number XXT01 to Bangwei Cao); Beijing Natural Science Foundation (grant number 7172061 to Bangwei Cao); the Capital Health Research and Development of Special (grant number 2018-2-2022 to Bangwei Cao); China Population Publicity and Education Center Research and Promotion Project (grant number 2017-A001 to Bangwei Cao).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharifman WH et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-3175.
2. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144.
3. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2454-2465.
4. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020-1030.
28. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S et al. "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial." Lancet 2016; 387: 1837-1846.

29. Sharma P, Retz M, Siefker-Radtke A, B, Necchi A, Bedke J et al. "Nivolumab in metastatic uterine cancer after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial." Lancet 2017; 18: 312-322.

30. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA et al. "Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite-unstable colorectal cancer (CheckMate 451): a randomised, open-label, multicentre, phase 2 study."

31. EI-Khoueiry AB, Sangrou B, Yau T, Crocenni TS, Kudo M, Hsu C et al. "Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, multicentre, phase 1/2 dose escalation and expansion trial." Lancet 2017; 389: 2492-2502.

32. Rosenberg JE, Hoffman-Censitz J, Powsle T, van der Heijden MS, Balar AV, Necchi A et al. "Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial." Lancet 2016; 387: 1909-1920.

33. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, van Pawel J et al. "Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): results from phase 3, open-label, multicentre randomised controlled trial." Lancet 2017; 389: 255-265.

34. Abol AP, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K et al. "Avelumab, an Anti-Programmed-Death-Ligand 1 Antibody, in Patients With Recurrent or Refractory Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study."

35. Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Lu J et al. "Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand 1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer." J Clin Oncol 2016; 34: 3119-3125.

36. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S et al. "Immune-related adverse events with immune checkpoint blockade: a comprehensive review." Eur J Cancer 2016; 54: 139-148.

37. Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaya NH. "Anti- PD-1-Related Pneumonitis during Cancer Immunotherapy." N Engl J Med 2015; 373: 288-290.

38. Tirumani SH, Ramaya NH, Keraliya A, Bailey NES, Ott PA, Hodi FS et al. "Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma..." J Clin Oncol 2016; 34: 1539-1545.

39. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al. "Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.

40. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al. "Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer." N Engl J Med 2017; 377: 1824-1835.

41. Carbone DP, Reck M, Paz-Ares L, Cr eelan B, Horn L, Steins M et al. "First-Line Pembrolizumab for Advanced Urothelial Cancer." JAMA 2017; 318: 1856-1867.

42. Remondino A, Cecotec J, Carbone DP, Paz-Ares L, Cerebini E, Nesi MT et al. "First-Line Pembrolizumab in Stage IV or Refractory Non-Small-Cell Lung Cancer." N Engl J Med 2017; 376: 2451-2462.

43. Ferris RL, Blumenschein GJ, Fayette J, Guajardo D, Coles V, Kirakosian A et al. "Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck." N Engl J Med 2016; 375: 1856-1867.

44. Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D et al. "Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma." Lancet Oncol 2018; 19: 672-681.
53. Eggermont AMM, Crittenden M, Wargo J. Combination Immunotherapy Development in Melanoma. Am Soc Clin Oncol Educ Book 2018; 197-207.

54. Larkin J, Chiariotto-Stileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373: 23-34.